The combination of sorafenib with MG149 synergistically suppresses the viability of patient-derived liver cancer cells. (A) Cell morphology of patient-derived liver cancer cell lines (AMC-H1 and AMC-H2). (B) MG149 enhanced the sensitivity to sorafenib at various concentrations in two patient-derived liver cancer cell lines. (n = 3). (C) At various concentrations, the synergistic effect between sorafenib and MG149 was corroborated by combination index (CI) values. (D) Relative cell confluency was considerably decreased in sorafenib + MG149 in AMC-H1 and AMC-H2 cells (n = 3). (E) PI images were acquired from IncuCyte Zoom software at the end of drug treatment. **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, not statistically significant.
